27th Annual EuroMeeting

Good pharmaceutical regulation creates value, poor regulation destroys value. This basic rule goes for public health value as well as for economic value. The current business model of the bio-pharmaceutical industry is predicated on robust regulation. Without regulation, there would be no drug development as we know it, and sponsors would not be able to claim public health value for their innovative products. Yet, regulation that produces no or only limited net health benefit may stifle innovation, disincentivise investors in R&D, and, most importantly, delay or deny patients access to beneficial treatments. Focussing on diabetes drugs as an illustrative example, this session will address how we can best find a level of evidence standards that maximises both public health and economic value.